News AbbVie's Humira finally faces biosimilar challenge in US AbbVie's cash-cow immunology product Humira has its first biosimilar competition in the US market with the launch of Amgen's copycat product Amjevita, several years after
News Amjevita, first Humira biosimilar approved – but no launch y... Amgen's biosimilar is ready to go, but AbbVie believes it can delay until 2022
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face